Literature DB >> 22494851

Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review.

M Garazi1, C Singer, J Tai, C C Ginocchio.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia is a significant nosocomial pathogen, responsible for an increasing number of infections, particularly in immunocompromised patients. AIM: This study describes the clinical and microbiological characteristics of patients with Stenotrophomonas maltophilia bacteraemia.
METHODS: We reviewed the charts of 102 patients with Stenotrophomonas maltophilia bacteraemia over a seven-year period from 2001 to 2007 in two tertiary care centres in New York, USA.
FINDINGS: There were 79 episodes (77.5%) related to nosocomial acquisition, 21 (20.6%) were healthcare-associated and two episodes (2%) were community-acquired. The most common source of bacteraemia was an infected central catheter in 44 patients (43.1%); 17 (16.6%) were related to neutropenic sepsis; nine (8.8%) were from an abdominal source; six (5.9%) were from a respiratory source, and the source of the bacteraemia was unclear in 26 cases (25.5%). The majority (94.1%) of the patients had central venous access devices. Intensive care unit stay, intubation, septic shock, neutropenia at the time of bacteraemia or carbapenem antibiotic use within 30 days of the episode were associated with mortality according to univariate analysis. By multivariate analysis, hypotensive shock and carbapenem use within 30 days of the episode were factors significantly correlated with mortality. The 102 isolates were mostly susceptible in vitro to trimethoprim-sulfamethoxazole (97.1%), levofloxacin (92.9%), ceftazidime (53.0%) and ticarcillin-clavulanic acid (49.2%).
CONCLUSION: Our data describe the characteristics of patients with Stenotrophomonas maltophilia bacteraemia and emphasize the importance of careful evaluation of vascular access devices in those patients.
Copyright © 2012 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22494851     DOI: 10.1016/j.jhin.2012.02.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  29 in total

1.  Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.

Authors:  Consuelo Velázquez-Acosta; Sugehily Zarco-Márquez; Mari Carmen Jiménez-Andrade; Patricia Volkow-Fernández; Patricia Cornejo-Juárez
Journal:  Support Care Cancer       Date:  2018-01-07       Impact factor: 3.603

2.  Structure of aminodeoxychorismate synthase from Stenotrophomonas maltophilia.

Authors:  Asim K Bera; Vesna Atanasova; Anjali Dhanda; Jane E Ladner; James F Parsons
Journal:  Biochemistry       Date:  2012-12-11       Impact factor: 3.162

3.  Child toy safety: An interdisciplinary approach to unravel the microbiological hazard posed by soap bubbles.

Authors:  Irene Amoruso; Chiara Bertoncello; Gianumberto Caravello; Valerio Giaccone; Tatjana Baldovin
Journal:  J Public Health Policy       Date:  2015-10-01       Impact factor: 2.222

4.  Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia.

Authors:  Ayesha Khan; Cedric Pettaway; Jennifer Dien Bard; Cesar A Arias; Micah M Bhatti; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

5.  Dengue co-infection in a blood stream infection caused by Stenotrophomonas maltophilia: A case report.

Authors:  Sreenivasan Srirangaraj; Arunava Kali; Sivaranjini Vijayan
Journal:  Australas Med J       Date:  2014-11-30

6.  Characterization of the Bacteriophage BUCT603 and Therapeutic Potential Evaluation Against Drug-Resistant Stenotrophomonas maltophilia in a Mouse Model.

Authors:  Pengjun Han; Wenjing Zhang; Mingfang Pu; Yahao Li; Lihua Song; Xiaoping An; Mengzhe Li; Fei Li; Shuyan Zhang; Huahao Fan; Yigang Tong
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

7.  A Stenotrophomonas maltophilia Strain Evades a Major Caenorhabditis elegans Defense Pathway.

Authors:  Corin V White; Brian J Darby; Robert J Breeden; Michael A Herman
Journal:  Infect Immun       Date:  2015-12-07       Impact factor: 3.441

8.  Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia.

Authors:  B Lakatos; B Jakopp; A Widmer; R Frei; H Pargger; L Elzi; M Battegay
Journal:  Infection       Date:  2014-03-14       Impact factor: 3.553

9.  Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.

Authors:  Ayesha Khan; Cesar A Arias; April Abbott; Jennifer Dien Bard; Micah M Bhatti; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

10.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.